Major Government Contract for Smallpox Vaccine Spurs Need for Compliance, Control and Scale; Ross’ Proven Expertise Supports Rapid Development of Acambis’ Manufacturing Function.
Acambis, a developer of vaccines to prevent and treat infectious diseases, completed a full implementation of Ross’ iRenaissance ERP system to support its operations. Acambis selected Ross’ iRenaissance enterprise software system to aid the integration and consolidation of its U.S. and U.K.-based operations, attain greater visibility into planning and production, improve inventory control and automate processes.
Acambis has a contract with the U.S. Centers for Disease Control and Prevention (“CDC”) to manufacture a stockpile of an investigational, second-generation smallpox vaccine. To meet the demands of this contract and its continued growth, Acambis turned to Ross’ iRenaissance to help increase operational and financial control of the business.
“Ross was selected by Acambis because it had the right combination of process manufacturing expertise, life sciences materials management know-how and quality assurance functionality for Acambis,” said Gordon Cameron, CEO. “iRenaissance has addressed the critical manufacturing issues that Acambis faced, ranging from meeting FDA requirements for cGMP, manufacturing and inventory costing, quality control, and bi-directional lot traceability.”
Ross’ iRenaissance solution helps Acambis to manage the manufacturing process to a level required by the biotechnology industry and U.S. Government: control over operational material for complete lot traceability, expiration date management, attribute tracking, formulation and recipe management, and integrated quality control. With Ross’ proven track record in pharmaceutical and biotechnology manufacturing and its ability to account for process-based costing in a validated, FDA-compliant environment, iRenaissance was ideally suited to address Acambis’ needs.
“Life sciences companies of all sizes face similar challenges specific to operational control and regulatory compliance issues,” said J. Patrick Tinley, CEO of Ross. “Ross has domain expertise in this complex vertical industry and has helped many emerging biotechnology companies successfully transition from R&D and clinical trials to in-house and outsourced commercial manufacturing. Our iRenaissance suite is built from the ground up to meet the critical business and operational requirements of biopharmaceutical companies like Acambis, which is undertaking a very important effort in countering the potential threat of smallpox.”
ERP Update provides articles, insights and commentary on enterprise resource planning issues.
